The estimated Net Worth of Scott Thomas Jackson is at least $221 Tysiąc dollars as of 20 May 2024. Mr. Jackson owns over 4,500 units of GlycoMimetics Inc stock worth over $720 and over the last 8 years he sold GLYC stock worth over $0. In addition, he makes $220,710 as Independent Director at GlycoMimetics Inc.
Scott has made over 1 trades of the GlycoMimetics Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently he exercised 4,500 units of GLYC stock worth $720 on 20 May 2024.
The largest trade he's ever made was exercising 4,500 units of GlycoMimetics Inc stock on 20 May 2024 worth over $720. On average, Scott trades about 196 units every 0 days since 2017. As of 20 May 2024 he still owns at least 4,500 units of GlycoMimetics Inc stock.
You can see the complete history of Mr. Jackson stock trades at the bottom of the page.
Scott T. Jackson serves as Independent Director of the Company. He has served as a member of our Board since November 2018. Mr. Jackson served as the Chief Executive Officer and as a member of the Board of Directors of Celator Pharmaceuticals, Inc. from April 2008 until July 2016, when the company was acquired by Jazz Pharmaceuticals plc. Mr. Jackson has more than 25 years of experience in the pharmaceutical and biotechnology industry and has held positions of increasing responsibility in sales, marketing and commercial development at Eli Lilly & Co., SmithKline Beecham, ImClone Systems Inc., Centocor Inc., a division of Johnson & Johnson, Eximias Pharmaceutical and YM BioSciences. He holds a B.S. in pharmacy from the Philadelphia College of Pharmacy and Science and an M.B.A. from the University of Notre Dame. Mr. Jackson presently serves on the board of directors of MacroGenics, Inc., a publicly traded pharmaceutical company, and the Board of Trustees of the Eastern Pennsylvania Chapter of The Leukemia and Lymphoma Society.
As the Independent Director of GlycoMimetics Inc, the total compensation of Scott Jackson at GlycoMimetics Inc is $220,710. There are 9 executives at GlycoMimetics Inc getting paid more, with Rachel King having the highest compensation of $2,689,070.
Scott Jackson is 55, he's been the Independent Director of GlycoMimetics Inc since 2018. There are 8 older and 8 younger executives at GlycoMimetics Inc. The oldest executive at GlycoMimetics Inc is Dr. John L. Magnani, 68, who is the Sr. VP of Research & Chief Scientific Officer.
Scott's mailing address filed with the SEC is C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE, MA, 02139.
Over the last 11 years, insiders at GlycoMimetics Inc have traded over $15,299,593 worth of GlycoMimetics Inc stock and bought 10,868,557 units worth $48,421,008 . The most active insiders traders include Scott D Sandell, Peter J Barris oraz M James Barrett. On average, GlycoMimetics Inc executives and independent directors trade stock every 51 days with the average trade being worth of $38,210. The most recent stock trade was executed by Public Equities, L.P.Invus ... on 7 August 2024, trading 322,361 units of GLYC stock currently worth $61,249.
at glycomimetics, we are committed to helping to make a difference in the lives of people living with sickle cell, cancer, and other serious diseases. our mission is to continue to advance our research and clinical candidates, providing hope for patients as we strive for tomorrow’s breakthrough treatments. glycomimetics is a clinical-stage biotechnology company. we use novel and proprietary glycobiology technology to develop treatments for diseases, particularly where there is high unmet need. since the company’s inception in 2003, we have developed a robust, diversified product pipeline. we are a public company traded on the nasdaq under the symbol glyc.
GlycoMimetics Inc executives and other stock owners filed with the SEC include: